SOUTH SAN FRANCISCO, Calif. — October 16, 2025 — Leads & Copy — Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced today that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, which is under investigation for treating chronic hepatitis B virus (HBV) infection.
The USAN Council, which includes members from the FDA, AMA, USP, and APhA, develops simple, informative, and unique generic drug names.
Lawrence Blatt, PhD, MBA, Chairman, President, and CEO of Aligos Therapeutics, stated that the adoption of pevifoscorvir sodium marks the first generic name for a compound at Aligos. He added that as the company continues to progress its Phase 2 B-Supreme study, they look forward to adopting this new name. This milestone showcases Aligos’ continued innovation in the liver and viral disease space and reinforces their commitment to improving patient outcomes.
Pevifoscorvir sodium, formerly known as ALG-000184, is an oral small molecule capsid assembly modulator (CAM-E) derived from IP licensed from Emory University and further optimized by Aligos. Phase 1 studies have demonstrated that pevifoscorvir sodium was well-tolerated, with no safety signals observed, and demonstrated linear PK and excellent antiviral activity. Longer-term Phase 1 studies have shown sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg.
The Phase 2 B-SUPREME study initiated in August 2025, with interim data projected in 2026, and topline data anticipated in 2027.
Investor Contact:
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact:
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
Source: Aligos Therapeutics, Inc.
